Suivre
Abonner PharmaMar

PharmaMar

http://

Filtre
  • 29.09.2006 – 10:12

    PharmaMar Reports New Data on Kahalalide-F and Aplidin(R) at ESMO Congress

    Istanbul, Turkey (ots/PRNewswire) - PharmaMar, the biopharmaceutical company specialising in cancer therapy, announces today that it is to present new data from two of its clinical compounds, Kahalalide F and Aplidin(R), at the 31st European Society for Medical Oncology Congress (ESMO) being held in Istanbul, Turkey from 29 September to 3 October 2006. Data will ...

  • 22.11.2005 – 09:26

    PharmaMar Presents Pharmacogenomic Data on Yondelis(R) at CTOS

    Boca Raton, Florida, November 22 (ots/PRNewswire) - PharmaMar announces the presentation of data from two research projects at the 11th Annual CTOS (Connective Tissue Oncology Society) Meeting, which took place in Florida, USA, from November 19-21, 2005. The first presentation highlighted data from a retrospective study conducted in tumour samples from patients of soft tissue sarcoma treated with Yondelis(R) in ...

  • 17.01.2005 – 08:25

    PharmaMar's Fifth Novel Compound, Zalypsis(R), Enters Clinical Development

    Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that Zalypsis(R) (PM00104/50), its fifth new marine derived compound, has begun Phase I clinical trials, already in patients, for the treatment of solid tumours. Zalypsis is a novel chemical entity related to the marine natural compounds Jorumycin and the family of Renieramycins, obtained from molluscs ...

  • 25.11.2004 – 08:32

    Aplidin(R) Enters Phase II Trials in Haematological Cancers

    Madrid, Spain, November 25 (ots/PRNewswire) - - Aplidin(R) now in Phase II trials in both solid and haematological cancers PharmaMar, the biopharmaceutical company specialising in cancer therapy, today announces that its marine derived anti-tumour agent, Aplidin(R), has commenced Phase II clinical trials in haematological malignancies, including studies in Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) ...